Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: A Spanish survey

Clinical and Translational Oncology

Volumn 15, Issue 6, 2013, Pages 477-483

  Steegmann, J L ^a   Sanchez Torres J M ^b,c   Colomer, R ^c   Vaz, A ^d   Lopez J ^d   Jalon I ^e   Provencio, M ^f   Gonzalez Martin A ^c   Perez M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL RUBER INTERNACIONAL   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Anaemia; Chemotherapy; Darbepoetin alfa; Haematological malignancies; Solid tumours; Transfusion

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM COMPLEX; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CHEMORADIOTHERAPY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; SOLID TUMOR; SPAIN; SYSTEMIC THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HEALTH SURVEYS; HEMATINICS; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; SPAIN; SURVIVAL RATE; YOUNG ADULT;

EID: 84878745722     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0953-5     Document Type: Article

References (28)

1. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634
2. Demetri G (2001) Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 84:31-37
3. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 91:2214-2221
4. Van Belle SJP, Cocquyt V (2003) Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 47:1-11
5. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26:132-149
6. Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33-36
7. Scrijvers D, Roila F (2009) Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use. Ann Oncol 20(Suppl 4):159-161
8. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293-2306
9. Guardiola E, Morschhauser F, Zambrowski JJ, Antoine EC (2007) Prise en charge de l'anemie chez les patients presentant une pathologie maligne: resultats de l'etude F-ACT (French Anaemia Cancer Treatment). Bull Cancer 94:907-914
10. Steinmetz T, Totzke U, Schweigert M, Mittermuller J, Nawka S, Tesch H, Groschek M, Soling U, Hellebrand E, Tsamaloukas A (2011) A prospective observational study of anaemia management in cancer patients - results from the German Cancer Anaemia Registry. Eur J Cancer Care (Engl) 20:493-502
11. Verbeke N, Beguin Y, Wildiers H, Canon JL, Bries G, Bosly A, Van Belle S (2012) High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008). Support Care Cancer 20:23-28
12. Birgegard G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers D, Shasha D, Van Belle S (2005) Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68(Suppl 1):3-11
13. Kosmidis P, Krzakowski M (2005) Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer 50:401-412
14. Barrett-Lee PJ, Ludwig H, Birgegard G, Bokemeyer C, Gascon P, Kosmidis PA, Krzakowski M, Nortier JW, Kongable G, Schneider M, Schrijvers D, Van Belle SJ (2006) Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 70:34-48
15. Aapro M, Abraham I, Bokemeyer C, Ludwig H, Macdonald K, Soubeyran P, Turner M (2008) The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. Support Care Cancer 16:193-200
16. Ludwig H, Aapro M, Bokemeyer C, Macdonald K, Soubeyran P, Turner M, Albrecht T, Abraham I (2009) Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 45:1603-1615
17. Alberola Candel V, Carrato Mena A, Diaz-Rubio Garcia E, Gascon Vilaplana P, Gonzalez Baron M, Martin Jimenez M, Alba Conejo E, Cassinello Espinosa J, Colomer R, Cruz Hernandez JJ, Barnadas i Molins A, Camps Herrero C, Casas Fernandez de Tejerina AM, Carulla Torrent J, Constenla Figueiras M, Gavila Gregori J, Isla Casado MD, Massuti Sureda B, Provencio Pulla M, Rodriguez Sanchez CA, Sanz Ortiz J (2009) Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. Clin Transl Oncol 11:727-736
18. Aapro M, Scherhag A, Burger HU (2008) Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 99:14-22
19. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Recombinant human erythropoiesis- stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373:1532-1542
20. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 23:6941-6948
21. Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT (2006) Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 28:801-831
22. Wauters I, Vansteenkiste J (2009) Darbepoetin alfa in the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther 9:221-230
23. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA (2009) Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 27:2838-2847
24. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714
25. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C (2007) A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 11:1-202, iii-iv
26. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H (2010) Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 102:301-315
27. Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK (2003) Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98:1514-1520
28. Aapro M (2009) An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. Oncologist 14(Suppl 1):1-5